Inflammatory cytokines correlated with clinical outcome of temporomandibular joint irrigation in patients with chronic closed lock

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 102, Issue 5, 2006, Pages 596-601

  Hamada, Yoshiki ^a   Kondoh, Toshirou ^b   Holmlund, Anders B ^c   Yamamoto, Matsuo ^d   Horie, Akihisa ^a   Saito, Tomoyuki ^a   Ito, Ko ^b   Seto, Kanichi ^a   Sekiya, Hideki ^e  

^a TSURUMI UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SHOWA UNIVERSITY   (Japan)

^e TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTHROSCOPY; ARTICLE; BIOSYNTHESIS; CHEMISTRY; CHRONIC DISEASE; DISLOCATION; FEMALE; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; LAVAGE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; OSTEOARTHRITIS; PROGNOSIS; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ARTHROSCOPY; CHRONIC DISEASE; DISLOCATIONS; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; INTERLEUKIN-8; IRRIGATION; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROGNOSIS; RANGE OF MOTION, ARTICULAR; STATISTICS, NONPARAMETRIC; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749660643     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2005.11.010     Document Type: Article

References (36)

1. Shafer D.M., Assael L., White L.B., and Rossomando E.F. Tumor necrosis factor-α as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J Oral Maxillofac Surg 52 (1994) 786-791
2. Fu K., Ma X., Zhang Z., and Chen W. Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders. J Oral Maxillofac Surg 53 (1995) 424-426
3. Kubota E., Kubota T., Matsumoto J., Shibata T., and Murakami K.-I. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg 56 (1998) 192-198
4. Sandler N.A., Buckley M.J., Cillo J.E., and Braun T.W. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 56 (1998) 534-543
5. Takahashi T., Kondoh T., Fukuda M., Yamazaki Y., Toyosaki T., and Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85 (1998) 135-141
6. Kaneyama K., Segami N., Nishimura M., Suzuki T., and Sato J. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Br J Oral Maxillofac Surg 40 (2002) 418-423
7. Nishimura M., Segami N., Kaneyama K., Sato J., and Fujimura K. Comparison of cytokine level in synovial fluid between successful and unsuccessful cases in arthrocentesis of the temporomandibular joint. J Oral Maxillofac Surg 62 (2004) 284-287
8. Kardel R., Ulfgren A.-K., Reinholt P., and Holmlund A. Inflammatory cell and cytokine patterns in patients with painful clicking and osteoarthritis in the temporomandibular joint. Int J Oral Maxillofac Surg 32 (2003) 390-396
9. van de Loo F.A.J., Joosten L.A.B., van Lent P.L.E.M., Arntz O.J., and van den Berg W.B. Role of interleukin-1, tumor necrosis factor a, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 38 (1995) 164-172
10. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
11. Verburgh C.A., Hart M.H.L., Aarden L.A., and Swaak A.J.G. Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions. Clin Rheumatol 12 (1993) 494-499
12. Lotz M., Terkeltaub R., and Villinger P.M. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. J Immunol 148 (1992) 466-473
13. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13 (1995) 251-276
14. Sakkas L.I., Johanson N.A., Scanzello C.R., and Platsoucas C.D. Interleukin-12 is expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis and osteoarthritis. Cell Immunol 188 (1998) 105-110
15. Fang P.-K., Ma X.-C., Ma D.-L., and Fu K.-Y. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-β1 in synovial fluid aspirates of patients with temporomandibular disorders. J Oral Maxillofac Surg 57 (1999) 922-928
16. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 (1991) 3815-3822
17. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
18. van Roon J.A.G., van Roy J.L.A.M., Gmelig-Meyling F.H.J., Lafeber F.P.J.G., and Bijlsma J.W.J. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 39 (1996) 829-835
19. Zardeneta G., Milam S.B., and Schmitz J.P. Elution of proteins by continuous temporomandibular joint arthrocentesis. J Oral Maxillofac Surg 55 (1997) 709-716
20. Kaneyama K., Segami N., Nishimura M., Sato J., Fujimura K., and Yoshimura H. The ideal lavage volume for removing bradykinin, interleukin-6, and protein from the temporomandibular joint by arthrocentesis. J Oral Maxillofac Surg 62 (2004) 657-661
21. Kondoh T., Dolwick M.F., Hamada Y., and Seto K. Visually guided irrigation for patients with symptomatic internal derangement of the temporomandibular joint: a preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 544-551
22. Hamada Y., Kondoh T., Holmlund A.B., Iino M., Nakajima T., and Seto K. Visually guided temporomandibular joint irrigation in patients with chronic closed lock: clinical outcome and its relationship to intra-articular morphologic changes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 552-558
23. Alstergren P., Appelgren A., Appelgren B., Kopp S., Lundeberg T., and Theodorsson E. Determination of temporomandibular joint fluid concentrations using vitamin B12 as an internal standard. Eur J Oral Sci 103 (1995) 214-218
24. Murakami K.-I., Hosaka H., Moriya Y., Segami N., and Iizuka T. Short-term treatment outcome study for the management of temporomandibular joint closed lock. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80 (1995) 253-257
25. Hamada Y., Kondoh T., Holmlund A.B., Nakajima T., Horie A., Saito T., et al. One-year clinical course following visually guided irrigation for chronic closed lock of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 (2006) 172-176
26. Nishimura M., Segami N., Kaneyama K., Suzuki T., and Miyamaru M. Proinflammatory cytokines and arthroscopic findings of patients with internal derangement and osteoarthritis of the temporomandibular joint. Br J Oral Maxillofac Surg 40 (2002) 68-71
27. Kubota E., Imamura H., Kubota T., Shibata T., and Murakami K.-I. Interleukin 1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 55 (1997) 20-27
28. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 (1998) 2196-2204
29. Choy E.H.S., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46 (2002) 3143-3150
30. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363 (2004) 675-681
31. Maini R.N., Breedveld F.C., Kalden J.P., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
32. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
33. Kim W.-U., Min S.-Y., Cho M.-L., Youn J., Min J.-K., Lee S.-H., et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol 119 (2000) 175-181
34. Smeets T.J.M., Kraan M.C., Versendaal J., Breedveld F.C., and Tak P.P. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 26 (1998) 2089-2093
35. Isomäki P., Luukkainen R., Saario R., Toivanen P., and Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 39 (1996) 386-395
36. Chernoff A.E., Granowitz E.V., Shapiro L., Lonnemann G., Angel J.B., Kennedy J.S., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154 (1995) 5492-5499